Vera Therapeutics Return On Equity vs. Total Debt
| VERA Stock | USD 46.46 0.46 0.98% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.94) | Current Value (0.90) | Quarterly Volatility 0.57704468 |
For Vera Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vera Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vera Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vera Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vera Therapeutics over time as well as its relative position and ranking within its peers.
Vera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vera Therapeutics Total Debt vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vera Therapeutics's current stock value. Our valuation model uses many indicators to compare Vera Therapeutics value to that of its competitors to determine the firm's financial worth. Vera Therapeutics is rated below average in return on equity category among its peers. It is rated third in total debt category among its peers . At present, Vera Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Vera Therapeutics' earnings, one of the primary drivers of an investment's value.Vera Total Debt vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Vera Therapeutics |
| = | -0.65 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Vera Therapeutics |
| = | 53.71 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Vera Total Debt vs Competition
Vera Therapeutics is rated third in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 1.46 Billion. Vera Therapeutics holds roughly 53.71 Million in total debt claiming about 4% of equities under Health Care industry.
Vera Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vera Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vera Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Vera Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Vera Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 251 K | 263.6 K | |
| Net Interest Income | 3.6 M | 3.8 M | |
| Interest Income | 6.9 M | 7.3 M | |
| Operating Income | -102 M | -96.9 M | |
| Net Loss | -102.8 M | -97.6 M | |
| Income Before Tax | -96 M | -91.2 M | |
| Total Other Income Expense Net | 6 M | 6.3 M | |
| Net Income Applicable To Common Shares | 102.4 M | 107.5 M | |
| Net Loss | -96 M | -91.2 M | |
| Income Tax Expense | 900.00 | 800.00 | |
| Non Operating Income Net Other | -2.6 M | -2.4 M | |
| Change To Netincome | 10.2 M | 7.4 M | |
| Net Loss | (2.25) | (2.36) | |
| Income Quality | 0.96 | 0.63 | |
| Net Income Per E B T | 1.00 | 1.10 |
Vera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vera Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vera Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vera Therapeutics' important profitability drivers and their relationship over time.
Use Vera Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Vera Therapeutics Pair Trading
Vera Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Vera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vera Therapeutics to buy it.
The correlation of Vera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vera Therapeutics position
In addition to having Vera Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
To fully project Vera Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vera Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vera Therapeutics' income statement, its balance sheet, and the statement of cash flows.